INNATE PHARMA (EPA:IPH) Innate Pharma (Euronext Paris: FR0010331421 – IPH) updates on its next meetings with analysts and investors

Transparency directive : regulatory news

23/03/2011 17:47

Press release

    INNATE PHARMA UPDATES ON ITS NEXT MEETINGS WITH ANALYSTS AND INVESTORS

Marseilles, France, March 23, 2011

Innate Pharma (the "Company" - Euronext Paris: FR0010331421 - IPH) announces
that it will participate to the following analyst and investor conferences in
the coming weeks:

* Benelux Midcap Event in Brussels, Belgium, on March 31 & April 1, 2011

* Paris Smallcap Event in Paris, France, on April 26 & 27, 2011

Innate Pharma is committed to meet on a regular basis with the financial
community. Investors can also find updated information on the company's
website (www.innatepharma.com) and contact the investor relations team by
writing to investors@innatepharma.com.

About Innate Pharma:

Innate Pharma S.A. is a biopharmaceutical company developing first-in-class
immunotherapy drugs for cancer and inflammatory diseases.

The Company specializes in the development of new monoclonal antibodies
targeting regulation pathways of innate immunity cells. Its most advanced
drug-candidate is IPH 2101, an anti-KIR monoclonal antibody potentiating NK
cells activation currently in Phase II clinical trials in hematologic cancers.
Two of its antibody programs in chronic inflammation are out-licensed to Novo
Nordisk A/S.

Innate Pharma's key expertise is in immunopharmacology and antibody
technology. The Company has implemented in-house a large panel of molecular
and cellular assays and in vivo models for assessing the pharmacodynamics and
pharmacotoxicology of drug candidates. In addition, Innate Pharma has access
to a very large set of unique research tools in cellular immunology through
its worldwide network of scientific collaborations.

Incorporated in 1999 and listed on NYSE-Euronext in Paris in 2006, Innate
Pharma is based in Marseilles, France, and had 86 employees as at
December 31, 2010.

Learn more about Innate Pharma at www.innate-pharma.com.

Practical Information about Innate Pharma shares:
ISIN code                     FR0010331421
Ticker code                   IPH

Disclaimer:
This press release contains certain forward-looking statements. Although the
company believes its expectations are based on reasonable assumptions, these
forward-looking statements are subject to numerous risks and uncertainties,
which could cause actual results to differ materially from those anticipated.
For a discussion of risks and uncertainties which could cause the company's
actual results, financial condition, performance or achievements to differ
from those contained in the forward-looking statements, please refer to the
Risk Factors ("Facteurs de Risque") section of the Document de Reference
prospectus filed with the AMF, which is available on the AMF website
(http://www.amf-france.org) or on Innate Pharma's website.
This press release and the information contained herein do not constitute an
offer to sell or a solicitation of an offer to buy or subscribe to shares in
Innate Pharma in any country.

For additional information, please contact:

Innate Pharma                   Alize Public Relations
Laure-Hélène Mercier            Caroline Carmagnol
Director, Investor Relations    Phone:  +33 (0)1 41 22 07 31
Phone: +33 (0)4 30 30 30 87     Mobile: +33 (0)6 64 18 99 59
investors@innate-pharma.com     caroline@alizerp.com

INNATE PHARMA's latest news

05/04/2024 09:34

INNATE PHARMA (EPA:IPH) Innate Pharma (Euronext Paris: FR0010331421 – IPH) updates on its next meetings with analysts and investors

Transparency directive : regulatory news

INNATE PHARMA's latest news

Other stories